ANG Lifesciences India Ltd

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has announced its Annual Report for FY 2025-26 and Notice convening the 20th Annual General Meeting (AGM) on September 30, 2026. The AGM will consider the audited standalone and consolidated financial statements, appointment of a director, ratification of cost auditor remuneration, and re-appointment of an independent director.

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has announced its standalone and consolidated unaudited financial results for the quarter ended 30th June 2026. The company reported a loss before exceptional items and tax of ₹(577.95) for the quarter, compared to a profit of ₹142.96 in the same period last year. The company's total expenses for the quarter were ₹2,298.49, compared to ₹2,477.77 in the same period last year. The company's net loss for the quarter was ₹424.42, compared to a net loss of ₹138.18 in the same period last year.

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has submitted its standalone and consolidated unaudited financial results for the quarter ended 30.06.2026. The company reported a loss before exceptional items and tax of ₹577.95, with a total tax expense of ₹133.53. The loss for the period was ₹424.42. The company's revenue from operations was ₹1,529.77, with a total revenue of ₹1,540.54.

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has scheduled a Board Meeting on 14/08/2026 to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30-06-2026.

ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended 30 June 2026, confirming the dematerialization of securities and listing on the stock exchange.